NASDAQ:GERN 12 December 2025

Geron Corporation stock is back in focus on December 12, 2025, as investors digest a sweeping restructuring tied to the company’s commercial push for RYTELO and its longer-term clinical ambitions. The headlines have been loud—one-third of the workforce is set to be cut, analysts are re-checking their models, and the market is weighing a familiar biotech question: is this the start of a leaner turnaround, or a sign that growth has stalled? Geron Corporation+2BioPharma Dive+2